Delivery Order HHSN261201200034I-HHSN26100011
Award Date 9/19/16
Potential Completion Date 9/18/23
Potential Value $2.2M
Federal Agency
Ultimate Awardee
NAICS Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Houston, TX 77030, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm fixed price delivery order contract awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract is part of the PREVENT Cancer Program, a preclinical research initiative focused on developing prevention strategies for breast cancer. The $714,123.60 contract supports "TARGETING THE MTOR PATHWAY FOR THE PREVENTION OF...
- The Department of Health and Human Services, National Institutes of Health, National Cancer Institute awarded a firm-fixed-price delivery order contract to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The $849,016 contract, which runs from September 17, 2018 to December 16, 2022, supports the "Rank Ligand Inhibition - A Potential Chemoprevention Strategy for Women at High Genetic Risk of Breast Cancer" project under the Preclinical...
- The National Cancer Institute (NCI) awarded a $2,067,521.23 delivery order contract to the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct early phase clinical research for the Cancer Prevention Agent Development Program. This contract is a child under the larger Cancer Prevention Agent Development Program 2012-2017 indefinite delivery vehicle. MD Anderson, as a comprehensive cancer research and treatment center, will provide various services in support of this cancer...
- This is a $1,686,205.95 delivery order contract awarded by the National Cancer Institute (NCI) to the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct a randomized pre-surgical clinical trial evaluating alternative dosing regimens of the cancer drug exemestane in postmenopausal women with early-stage estrogen receptor-positive breast cancer. The contract is part of NCI's Cancer Prevention Agent Development Program, which supports early phase clinical research on new...
- This is a three-year, $13,481,325.00 definitive contract awarded by the National Cancer Institute (NCI) to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract supports a Phase II chemoprevention clinical trial in patients with adenomatous polyposis coli, a genetic condition that increases cancer risk. The contract does not have a small business set-aside designation. MD Anderson Cancer Center, a comprehensive cancer research and...
- This is a firm fixed-price delivery order contract awarded by the National Institutes of Health (NIH) National Cancer Institute to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, for a "Targeted Casein Kinase Inhibition as a Breast Cancer Prevention" research project. The $505,743.00 contract, which has no set-aside designation, was awarded on June 20, 2017 and is scheduled for completion by December 31, 2019. The contract falls under...
- This federal contract award is for a multicenter Phase II clinical study of docosahexaenoic acid (DHA) in patients with a history of breast cancer, premalignant lesions, or benign breast disease. The $716,626.48 award was made to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System, by the National Cancer Institute under the Cancer Prevention Agent Development Program. The period of performance is from September 2014 to March 2016, with a final...
- This is a federal contract award from the National Cancer Institute (NCI) to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System, for a pilot study of the drug denosumab in BRCA1/2 mutation carriers scheduled for risk-reducing salpingo-oophorectomy. The $976,432.58 cost-reimbursement contract is part of the NCI's Cancer Prevention Agent Development Program, supporting early phase clinical research. It was awarded on September 21, 2017 with a...
- This is a delivery order awarded by the Department of Health and Human Services' National Institutes of Health's National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The $1,219,899.79 firm fixed price contract supports cancer prevention research through vaccination against induced antigens, as part of the PREVENT Preclinical Drug Development Program. The contract does not have a set-aside designation. MD Anderson Cancer...
- This federal contract award, valued at $1,272,481.00, was issued by the National Cancer Institute to The University of Texas M.D. Anderson Cancer Center, a child entity of the University of Texas System. The contract is part of the "PREVENT Preclinical Drug Development Program (PREVENT)" and is focused on "TARGETING THE A2B ADENOSINE RECEPTOR FOR IMMUNOPREVENTION OF PANCREATIC CANCER." It is a firm fixed-price delivery order contract with a completion date of March 14,...